%0 Journal Article
%T Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study.
%A Arecco L
%A Latocca MM
%A Blondeaux E
%A Riccardi F
%A Mocerino C
%A Guarneri V
%A Mioranza E
%A Bisagni G
%A Gasparini E
%A Puglisi F
%A Membrino A
%A Ferro A
%A Adamo V
%A Giovanardi F
%A Tamberi S
%A Donati S
%A Landucci E
%A Biganzoli L
%A Piccinini S
%A Pastorino S
%A de Azambuja E
%A Poggio F
%A Lambertini M
%A Del Mastro L
%J Breast
%V 77
%N 0
%D 2024 Jul 9
%M 39043079
%F 4.254
%R 10.1016/j.breast.2024.103769
%X <B>BACKGROUND: </B>Most premenopausal patients with early breast cancer (eBC) are diagnosed with hormone receptor-positive disease and therefore candidate for adjuvant endocrine therapy (ET).<BR><B>METHODS: </B>The Gruppo Italiano Mammella (GIM) 23-POSTER (GIM23) is a multicenter, prospective, observational study conducted in 26 Italian institutions, aiming to evaluate ET choices for premenopausal patients affected by hormone receptor-positive eBC in a real-world setting. Here we report also the results in terms of type of ET prescribed according to the definition of high-risk patients by monarchE and NATALEE trials.<BR><B>RESULTS: </B>Between October 2019 and June 2022, 600 premenopausal patients were included, with a median age of 46 years. Almost half (271, 45.2 %) of the patients had stage I disease, while 254 (42.3 %) and 60 (10.0 %) patients had stage II and III, respectively. Overall, 149 (25.1 %) patients received tamoxifen alone, 83 (14.0 %) tamoxifen with ovarian function suppression (OFS), while 361 (60.9 %) received aromatase inhibitor (AI) with OFS. Patients treated with AI and OFS had higher number of metastatic axillary nodes, higher grade and more often received chemotherapy (all p < 0.001). According to the inclusion criteria of the monarchE and NATALEE trials, 81 patients (15.6 %) were considered high-risk for the monarchE and received AI with OFS in 88.9 % of the cases, while 231 patients (44.4 %) were considered high-risk for the NATALEE trial and received AI with OFS in 74.5 % of cases.<BR><B>CONCLUSIONS: </B>AI with OFS is the most prescribed adjuvant ET among premenopausal patients, especially in the presence of high-risk features.